Genetic Testing (PGT/PGD) in Madhya Pradesh: A Complete Clinical Guide for Couples Pursuing IVF

Preimplantation Genetic Testing (PGT) is a broad clinical term that encompasses several distinct procedures performed on embryos created through IVF before they are transferred to the uterus. It replaced the older umbrella term Preimplantation Genetic Diagnosis (PGD), which is still widely used by patients and clinicians in India.

There are three main types. PGT-A (formerly PGS) screens embryos for aneuploidy — meaning an abnormal number of chromosomes — which is the leading cause of failed implantation and early miscarriage. PGT-M (formerly PGD) is used when one or both parents carry a known single-gene mutation, such as thalassaemia, cystic fibrosis, spinal muscular atrophy, or Huntington's disease. PGT-SR is used when a parent carries a structural chromosomal rearrangement, such as a translocation, that could lead to repeated pregnancy loss.

In clinical practice across Madhya Pradesh, PGT-A is by far the most commonly requested type, particularly for women over 35, couples with recurrent miscarriage, and those who have experienced repeated IVF failure. PGT-M requires an additional preparatory phase — often called a 'workup' — during which the laboratory designs probes specific to the family's mutation. This workup can take 8 to 12 weeks and must be completed before the actual IVF cycle begins.

Not every IVF patient in Madhya Pradesh will require or benefit from PGT, but there are well-defined clinical indications that make it strongly advisable. Understanding whether you fall into one of these groups is a crucial first conversation to have with your fertility specialist.

Women aged 35 and above have a significantly higher rate of chromosomally abnormal eggs. By 40, studies suggest that more than 50% of embryos may carry aneuploidies. PGT-A helps identify the euploid (chromosomally normal) embryos most likely to result in a healthy live birth, reducing the number of failed transfers and the emotional burden of repeated cycles.

Couples who have experienced two or more miscarriages should also consider PGT evaluation. In Bhopal and Indore, recurrent pregnancy loss is often under-investigated, with couples cycling through multiple pregnancies before genetic testing is suggested. PGT-SR is specifically designed for couples where one partner carries a balanced translocation — a structural chromosomal change that is harmless to the carrier but significantly increases miscarriage risk in pregnancy.

Finally, couples with a family history of hereditary conditions — thalassaemia is especially prevalent in central India, including communities across Madhya Pradesh — should discuss PGT-M. Carrier screening before conception, combined with PGT-M during IVF, can prevent the birth of an affected child while allowing a biological pregnancy.

Madhya Pradesh has a significant carrier burden for several genetic conditions that make preimplantation genetic testing particularly relevant for its population. Thalassaemia, both alpha and beta variants, is prevalent in tribal communities and across many districts of the state. When both partners are carriers of beta-thalassaemia, each pregnancy carries a 25% risk of producing a child with thalassaemia major — a severe, lifelong condition requiring regular blood transfusions.

Sickle cell anaemia has an even higher prevalence in Madhya Pradesh compared to the national average, particularly among Scheduled Tribe communities in districts like Mandla, Dindori, Balaghat, and Chhindwara. The state has active government screening programmes, but these typically operate postnatally or during pregnancy rather than before conception. PGT-M offers these at-risk couples a proactive option: to select only unaffected embryos for transfer.

Other conditions where PGT-M is clinically relevant include spinal muscular atrophy (SMA), fragile X syndrome, Huntington's disease, and BRCA1/2 mutations for families with strong histories of hereditary breast and ovarian cancer. The HomeIVF Medical Board recommends that any couple in Madhya Pradesh with a known or suspected hereditary condition consult a clinical geneticist alongside their fertility specialist before beginning IVF, so an appropriate PGT-M workup can be initiated in time.

Understanding the clinical pathway for PGT helps couples plan realistically — both emotionally and logistically. The process integrates within a standard IVF cycle but adds specific steps that require coordination between the fertility clinic, the embryology laboratory, and a specialist genetic testing laboratory.

Step one is the stimulation phase, identical to a standard IVF cycle. The woman undergoes ovarian stimulation using injectable hormones over 10 to 14 days, monitored with ultrasound scans. Step two is egg retrieval, performed under sedation. The retrieved eggs are then fertilised with sperm in the laboratory to create embryos.

Step three is embryo culture. The embryos are grown in a controlled laboratory environment for 5 to 6 days until they reach the blastocyst stage — a more developed, robust stage suitable for biopsy. At day 5 or 6, the embryologist carefully removes a small cluster of cells (typically 5–8 cells) from the outer layer of the blastocyst called the trophectoderm. These cells are destined to form the placenta, not the baby, so the biopsy does not harm the embryo's developmental potential.

Step four is genetic analysis. The biopsied cells are sent to a specialist genetics laboratory — in India, these are often located in cities like Mumbai, Hyderabad, or Bengaluru — and results return in approximately 10 to 14 working days. Step five is a frozen embryo transfer (FET), where a chromosomally normal embryo is transferred in a subsequent cycle once results are available. Couples in Gwalior and Jabalpur should factor in this two-cycle timeline when planning PGT.

HomeIVF delivers a model of care that is particularly valuable for couples in Madhya Pradesh where specialist fertility services are often concentrated in a few urban centres. Through the HomeIVF platform, patients receive structured guidance from senior reproductive medicine specialists and genetic counsellors — without needing to relocate to another city or take repeated days off work for clinic visits.

HomeIVF coordinates the full PGT pathway: from initial carrier screening and genetic counsellor consultation, to identifying the right IVF centre equipped for blastocyst biopsy, to liaising with accredited genetic testing laboratories for timely results. For couples in Bhopal and Indore, HomeIVF helps map the nearest clinic with proven PGT capability. For patients in smaller towns like Sagar, Rewa, or Ujjain, the platform can facilitate monitoring scans locally while the embryology and biopsy work is handled at a well-equipped centre.

HomeIVF also offers IVF packages starting from ₹1.5 lakh, with transparent add-on structures for PGT so couples understand the full cost before committing. The HomeIVF Medical Board reviews every patient's case summary and provides personalised recommendations — ensuring that no couple is advised to undergo PGT unnecessarily, and no couple who genuinely needs it is left without access simply because they live outside a major city.

Receiving PGT results is a moment of significant anxiety for most couples, and understanding how to interpret them is important. Results typically classify each embryo as euploid (normal chromosome count), aneuploid (abnormal chromosome count), or mosaic (a mixed result with some normal and some abnormal cells).

Euploid embryos are recommended for transfer first. They carry the highest probability of successful implantation and a healthy live birth. Aneuploid embryos are not transferred, as they are highly unlikely to result in a successful pregnancy and are associated with miscarriage or significant chromosomal conditions. Mosaic embryos occupy a nuanced middle ground — current clinical guidance from bodies like PGDIS (Preimplantation Genetic Diagnosis International Society) suggests that low-level mosaic embryos may be transferred in certain circumstances, particularly when no euploid embryos are available, but only with detailed counselling.

It is important for couples in Madhya Pradesh to understand that PGT does not guarantee a live birth — it significantly improves the odds by selecting the most viable embryo. A normal PGT result does not screen for all possible genetic conditions, and standard prenatal testing during pregnancy (such as NIPT or amniocentesis) remains advisable. The HomeIVF Medical Board ensures every couple receives a thorough post-results counselling session before proceeding to transfer.

Despite the clinical value of PGT, several barriers prevent many couples in Madhya Pradesh from accessing it. The first is awareness: a significant proportion of couples undergoing IVF in tier-2 cities like Gwalior or Jabalpur are simply not informed that genetic testing of embryos is an option, particularly for recurrent failure or carrier status.

The second barrier is infrastructure. Not every IVF centre in Madhya Pradesh has the embryology capability to perform blastocyst-stage biopsy and vitrification (rapid freezing) to the standard required for PGT. Sending biopsied cells to specialist genetics laboratories also requires a robust cold-chain logistics system, which smaller clinics may lack.

The third barrier is cost uncertainty. Many couples assume PGT is prohibitively expensive and do not ask about it. In reality, while PGT does add to the overall IVF investment, the cost of an unnecessary failed transfer or a miscarriage — financially and emotionally — is often far greater.

HomeIVF addresses all three barriers directly. The platform provides educational resources and genetic counsellor access in regional languages. It partners only with centres that meet defined quality benchmarks for embryo biopsy and vitrification. And it presents costs transparently, helping couples in Bhopal and across Madhya Pradesh make informed decisions without surprises.

It is important that couples approach PGT with accurate expectations rather than assumptions that it guarantees success. IVF success rates in India typically range from 40–55% per cycle depending on age and the underlying cause of infertility. When PGT-A is used to select euploid embryos, the per-transfer success rate improves — but the degree of improvement depends on the patient's age, ovarian reserve, uterine health, and the quality of the laboratory.

For women under 35 with no prior IVF failure, PGT-A may not add significant benefit over standard IVF with good-quality blastocyst selection, and the HomeIVF Medical Board is transparent about this. For women over 38, those with recurrent implantation failure, or carriers of known genetic mutations, the clinical evidence supporting PGT is substantially stronger.

A realistic archetype of a HomeIVF patient who benefited from PGT might be a couple from Indore in their late 30s who had experienced two failed IVF cycles and one miscarriage. After PGT-A identified one euploid embryo among four blastocysts, a single frozen embryo transfer resulted in a successful ongoing pregnancy. This is not a guarantee, but it reflects the targeted, evidence-based approach that genetic testing enables — replacing repeated guesswork with informed embryo selection.